Pharma — India Patent Cases
1,090 decisions indexed
Page 36 of 37 · 1,090 total
Dr. Anji Reddy (Appellant) v.Hoechst Aktiengesellschaft
The Madras High Court allowed an appeal filed by Hoechst Aktiengesellschaft against a single judge's decision, restoring the original trademark registration order. The dispute centered on whether the mark 'Novigan,' applied for in Class 5 (pharmaceutical preparations), was deceptively similar to the existing registered mark 'Novalgin.' The court found that despite structural similarities, the marks were phonetically and visually distinct enough not to cause confusion among the general public. This ruling emphasizes deference to technical authorities like the Assistant Registrar when assessing trademark similarity.
Dr. Anji Reddy v.Hoechst Aktiengesellschaft
This appeal concerned the registrability of the pharmaceutical trademark 'Novigan' against an objection raised by the owner of 'Novalgin'. The single judge had ruled that the marks were deceptively similar, but the Madras High Court overturned this decision. The court found no significant phonetic or visual similarity between the two marks, noting that common prefixes like 'Nova' are widely used in the pharmaceutical sector. Consequently, the original order allowing registration was restored.
Astrazeneca Uk Ltd. v.Orchid Chemicals And Pharmaceuticals
The Delhi High Court ruled in favor of the defendant, Orchid Chemicals, vacating an earlier interim injunction that had restrained them from using the trademark 'MEROMER'. The court found that while the plaintiff (Astrazeneca) claimed infringement based on deceptive similarity with 'MERONEM', the balance of convenience favored the defendant. Given that the defendant offered a cheaper alternative for the same essential drug, and considering other companies also used similar prefixes in the market, the court allowed the use of 'MEROMER' but mandated regular submission of sales accounts to safeguard the plaintiff's interests.
Cadila Healthcare Limited v.Lupin Laboratories Ltd.
This Gujarat High Court judgment addressed a critical jurisdictional dispute regarding trademark infringement suits. Cadila Healthcare challenged the jurisdiction of the Fast Track Court, arguing that Section 134 of the Trade Marks Act mandates such cases be heard only by a District Court. The Court ultimately rejected this contention, ruling that due to the structural provisions linking Fast Track Courts and Additional Judges to the District Judge's cadre, the Fast Track Court possesses the necessary jurisdiction to try the suit.
Glaxo Smith Kline Plc And Ors. v.Controller Of Patents And Designs And ...
Glaxo Smith Kline challenged the rejection of their application for exclusive marketing rights. The core dispute revolved around whether the Controller was legally obligated to consider the examiner's report when making the final decision under Section 24A of the Patents Act, 1970. The Court set aside the impugned order and remanded the matter for a fresh decision based on the law existing at the time of the initial rejection.
Novartis Ag v.Natco Pharma Ltd.
Natco Pharma Ltd. opposed the patent application filed by Novartis Ag for a specific crystalline form of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not meet the criteria for enhanced efficacy under Section 3(d). Consequently, the application was refused.
Novartis Ag v.Cipla Ltd.
Cipla Ltd. opposed Novartis Ag's patent application for the ß-crystal form of imatinib mesylate. The Tribunal found that the invention was merely a new form of a known substance and did not demonstrate significant enhancement in efficacy as required under Section 3(d). Furthermore, the application was disqualified for wrongly claiming priority.
Novartis Ag v.Ranbaxy Laboratories Ltd.
Ranbaxy Laboratories Ltd., on behalf of Lakshmi Kumaran & Sridharan, opposed Novartis AG's patent application for a specific crystalline form (ß-crystal) of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not demonstrate enhanced efficacy as required under Section 3(d), leading to the refusal of the patent.
Novartis Ag v.Cancer Patients Aid Association.
The opposition was filed against Novartis AG's patent application for a specific crystalline form (ß-crystal) of imatinib mesylate. The Tribunal found that the invention was anticipated by prior art and did not meet the enhanced efficacy requirement under Section 3(d), leading to the refusal of the patent application.
Novartis Ag v.Hetero Drugs Limited
Novartis AG applied for a patent on the ß-crystal form of imatinib mesylate. Hetero Drugs Limited opposed the application, arguing that the invention was anticipated by prior art and did not meet the enhanced efficacy criteria under Section 3(d) of the Patents Act, 1970. The Tribunal agreed with the opposition, finding that the subject matter was a new form of a known substance without significant improvement in efficacy.
Glaxosmithkline Pharmaceuticals v.Theodar Laboratories Private Limited
The Delhi High Court ruled in favor of Glaxosmithkline Pharmaceuticals, granting a permanent injunction against Theodar Laboratories Private Limited for infringing on its trademarked product's packaging. The court found that the defendant's carton was a 'slavish imitation' of the plaintiff's distinctive color scheme and layout, which would mislead innocent consumers purchasing animal supplements. This judgment reinforces the protection afforded to trade dress in the pharmaceutical/feed supplement sector.
Pfizer Products Inc. v.Mr. Altamash Khan And Anr.
The Delhi High Court ruled in favor of Pfizer Products Inc., granting an interim order for the transfer of the domain name 'viagra.in' from the defendant to the plaintiff. The court recognized that a domain name is a valuable asset entitled to protection similar to a trademark, especially when it creates confusion or constitutes cyber squatting. This decision underscores the critical importance of securing digital real estate for major brands in the e-commerce era.
Wockhardt Limited v.Hetero Drugs Limited
Wockhardt Limited, holding a Process Patent and Exclusive Marketing Right (EMR) for Nadifloxacin 1% Cream, filed suit against Hetero Drugs Limited and others alleging patent infringement. The lower court had previously vacated an interim injunction granted to Wockhardt. This Division Bench set aside the single judge's order, finding that Wockhardt was entitled to an injunction due to a prima facie case and the risk of irreparable injury.
Wockhardt Ltd. v.Hetero Drugs Ltd. And Ors.
Wockhardt Ltd. filed Original Applications seeking an ad-interim injunction against Hetero Drugs Ltd. and others for infringing Patent No. 188847, Patent No. 188347, and EMR No. EMR/1/03 related to Nadifloxacin 1% cream (NADIDERM). The Madras High Court ultimately vacated the interim injunction, finding that the respondent had a valid manufacturing license based on US and Japan patents, and the challenge to this license was still pending before the Delhi High Court.
Pfizer Ltd. v.Commissioner Of Central Excise
The appellant (a medicament manufacturer) entered into an agreement with Pfizer Inc. to receive technical know-how and use patented technology for manufacturing pharmaceuticals. The Department levied Service Tax on payments made to Pfizer, classifying it as 'engineering consultancy'. The Tribunal ruled that since the transaction was a license/transfer of intellectual property know-how, not professional engineering advice, the levy of Service Tax was unwarranted.
N/A v.N/A
The Lok Sabha debated the Patents (Amendment) Bill, 2005, which sought to introduce product patents. Opposition members strongly argued that this change would lead to exorbitant drug prices, making essential medicines inaccessible to the common man, thereby violating the fundamental right to health under Article 21. Despite these concerns, the Minister of Commerce and Industry successfully moved the motion, and the Bill was ultimately passed by the House.
The Government of India v.Concerned Citizens/Pharmaceutical Industry Stakeholders
The debate centered on the introduction of a Bill to further amend the Patents Act, 1970. Opponents argued that the amendment would compromise India's strong generic drug industry and restrict public access to affordable life-saving medicines. The Speaker ultimately allowed the motion for introducing the Bill to be adopted.
Novartis Ag And Anr. v.Mehar Pharma And Anr.
Novartis sought an interim injunction restraining Mehar Pharma from manufacturing, selling, or exporting its anti-cancer drug 'VEENAT', which was alleged to infringe Novartis's Exclusive Marketing Rights (EMR) for 'B-crystalline form of imatinib Mesyiate salt'. The court ultimately denied the temporary injunction, citing concerns about disrupting the supply of this life-saving drug in India.
Intas Laboratories Pvt. Ltd. And Anr. v.Novaritis A.G., Schwarzwaldallee,
The dispute concerned the validity of an Exclusive Marketing Right (EMR) granted to Novaritis for the anti-cancer drug, Beta-Crystalline form of Imatinib Mesylate. Intas Laboratories challenged this EMR, arguing it created a monopoly and harmed public interest due to high pricing. The Madras High Court confirmed the interim injunction but mandated that the plaintiffs supply the drug freely to eligible patients.
Novartis Ag v.Adarsh Pharma And Anr.
The plaintiff, Novartis Ag, sought to confirm an ex parte injunction granted under Exclusive Marketing Rights (EMR) for its product, Beta Crystalline form of Imatinib Mesylate. The defendant challenged this injunction, arguing that no patent was ever filed in India and the EMR was vague. The court ultimately confirmed the injunction, finding prima facie materials favored the plaintiffs.
Exphar SA v.Eupharma Laboratories Ltd.
This Supreme Court judgment addressed a dispute concerning the trademark 'Maloxine' and its distinctive packaging design. The appellants, claiming ownership of the copyright and trademark, sued the respondents for passing off and copyright infringement related to the malaria medicine. A key legal challenge was whether the Delhi High Court had territorial jurisdiction over the matter. The court ultimately ruled that the receipt of a cease and desist notice within the jurisdiction was sufficient to invoke the court's authority.
Sun Pharmaceutical Industries Limited v.Wyeth Holdings Corporation And Anr.
The Bombay High Court dismissed the appeal filed by Sun Pharmaceutical Industries Limited against an interim order favoring Wyeth Holdings Corporation. The core dispute involved alleged infringement and passing off, where Wyeth held the registered trademark 'Pacitane' for anti-spasmodic preparations, and Sun used 'Parkitane'. The court found that due to the identical field of activity, common composition (Trihexylphenidyl), and high likelihood of consumer confusion, the appellants' use was fraudulent. Consequently, the court upheld the protective order granted to Wyeth.
Glaxo Group Ltd. v.Paun And Paum Chemicals
The Delhi High Court ruled in favor of Glaxo Group Ltd., finding that the defendant was infringing its trademarks 'Ostocalcium' and 'Ostocalcium Vet,' as well as engaging in passing off. The court found that the defendant's use of 'Oscal-Vet, D3' and the deceptively similar color scheme and get-up of its packaging material were likely to confuse the public. Consequently, a permanent injunction was granted, along with orders for the delivery up of infringing materials and rendition of accounts.
Usv Limited v.Systopic Laboratories Limited And Anr.
Usv Limited sought an injunction against Systopic Laboratories Limited for using trademarks (PIO, PIO-15, PIO-30) deemed deceptively similar to its own (PIOZ-15, PIOZ-30). The Madras High Court ultimately dismissed the application. The court held that the word 'PIO' is publici juris, meaning it describes the chemical ingredient and cannot be monopolized by a single party. Furthermore, the applicant failed to obtain leave to sue the first respondent and was found to have deliberately provided a false address for service, undermining its claim.
East African (I) Remedies Pvt. Ltd. v.Wallace Pharmaceuticals Ltd. And Anr.
The Delhi High Court dismissed the plaintiff's application seeking an ad interim injunction against trademark infringement. The court found that the plaintiff failed to establish a strong prima facie case, noting low historical sales figures and lack of evidence regarding goodwill. Conversely, the defendant demonstrated bona fide use, prior searches, and significant market presence with their product 'REVOX'. Consequently, the balance of convenience favored the defendant, who was allowed to continue manufacturing while being directed to deposit security for the plaintiff's interest.
Exphar Sa And Ors. v.Bharat Shah And Anr.
This appeal involved disputes concerning the trademark MALOXINE and associated copyright in its carton design. The plaintiffs, a Belgian-based company, sought permanent prohibitory injunctions against the defendants for passing off and infringement. However, the Delhi High Court ultimately ruled that it lacked the necessary territorial jurisdiction to entertain the suit or grant an interim injunction, as the plaintiff did not reside or carry on business within India.
Torrent Pharmaceuticals Ltd. v.The Wellcome Foundation Ltd.
The Gujarat High Court upheld the refusal of trademark registration for 'TROVIREX' filed by Torrent Pharmaceuticals Ltd. The court found that TROVIREX was deceptively similar to Wellcome Foundation Ltd.'s registered trademarks, ZOVIREX and ZOVIREX, particularly because both marks were used in relation to pharmaceutical products (similar goods). Citing established legal principles, the court concluded that allowing the registration would likely deceive consumers and cause confusion regarding the origin of the medicinal preparations.
Dr. Reddy's Laboratories Limited v.Manu Kosuri And Anr.
Dr. Reddy's Laboratories successfully sued defendants for cybersquatting and trademark infringement related to the domain name 'drreddyslab.com'. The court ruled that a domain name functions similarly to a trademark on the internet, granting it equal protection against passing off. Given the high similarity between the marks, the court found there was a clear likelihood of confusion among consumers. Consequently, the defendants were permanently restrained from using the infringing domain and were ordered to transfer 'drreddyslab.com' to Dr. Reddy's.
Richardson Vicks Inc. v.Raj Remedies
The plaintiffs (Richardson Vicks Inc.) sought an injunction against the defendants (Raj Remedies) alleging infringement of their registered trade mark 'VICKS' and copyright in the artistic label, by using the deceptively similar marks/get-up like 'VIKAS'. The Gujarat High Court upheld the City Civil Court's interim order, finding that a prima facie case for deceptive similarity existed.
Brawn Laboratories Ltd. v.Rhone Poulenc Rorer S.A.
The petitioner sought arbitration and an interim injunction under Section 9 of the Arbitration and Conciliation Act, 1996, to restrain the respondents from marketing products like CLEXANE. The dispute centered on the termination of an exclusive license agreement and alleged breach of negative covenants.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.